Lowest Price Guaranteed
Pages
274
Last Updated
October 2026
View Count
21873
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Point-of-Care Diagnostics (POCDs)
3.2.1. Characteristics of an Ideal Point-of-Care Diagnostic
3.2.2. Technologies Used in Point-of-Care Diagnostics of Infectious Diseases
3.3. Challenges Associated with Point-of-Care Diagnostics
3.4. Future Perspectives
4. CURRENT MARKET LANDSCAPE (FOCUS ON COVID-19)
4.1. Chapter Overview
4.2. Point-of-Care Diagnostics for COVID-19: List of Products
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Product
4.2.3. Analysis by Type of Technology
4.2.4. Analysis by Type of Sample
4.2.5. Analysis by Sensitivity Range
4.2.6. Analysis by Specificity Range
4.2.7. Analysis by Turnaround Time
4.3. Point-of-Care Diagnostics for COVID-19: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size and Geographical Location
4.3.3. Leading Developers: Analysis by Number of Products
4.3.4. World Map Representation: Analysis by Regional Activity
5. CURRENT MARKET LANDSCAPE (FOCUS ON TROPICAL DISEASES)
5.1. Chapter Overview
5.2. Point-of-Care Diagnostics for Tropical Diseases: List of Products
5.2.1. Analysis by Status of Development
5.2.2. Analysis by Type of Product
5.2.3. Analysis by Type of Technology
5.2.4. Analysis by Target Disease Indication
5.2.5. Analysis by Type of Sample
5.2.6. Analysis by Sensitivity Range
5.2.7. Analysis by Specificity Range
5.2.8. Analysis by Turnaround Time
5.3. Point-of-Care Diagnostics for Tropical Diseases: List of Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size and Geographical Location
5.3.3. Leading Developers: Analysis by Number of Products
5.3.4. World Map Representation: Analysis by Regional Activity
6. CURRENT MARKET LANDSCAPE (FOCUS ON RESPIRATORY INFECTIONS)
6.1. Chapter Overview
6.2. Point-of-Care Diagnostics for Respiratory Infections: List of Products
6.2.1. Analysis by Status of Development
6.2.2. Analysis by Type of Product
6.2.3. Analysis by Type of Technology
6.2.4. Analysis by Target Disease Indication
6.2.5. Analysis by Type of Sample
6.2.6. Analysis by Sensitivity Range
6.2.7. Analysis by Specificity Range
6.2.8. Analysis by Turnaround Time
6.3. Point-of-Care Diagnostics for Respiratory Infections: List of Developers
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size and Geographical Location
6.3.3. Leading Developers: Analysis by Number of Products
6.3.4. World Map Representation: Analysis by Regional Activity
7. CURRENT MARKET LANDSCAPE (FOCUS ON HIV/AIDS AND HEPATITIS)
7.1. Chapter Overview
7.2. Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Products
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Product
7.2.3. Analysis by Type of Technology
7.2.4. Analysis by Target Disease Indication
7.2.5. Analysis by Type of Sample
7.2.6. Analysis by Sensitivity Range
7.2.7. Analysis by Specificity Range
7.2.8. Analysis by Turnaround Time
7.3. Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size and Geographical Location
7.3.3. Leading Developers: Analysis by Number of Products
7.3.4. World Map Representation: Analysis by Regional Activity
8. OVERALL MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Analysis by Type of Technology
8.3. Analysis by Target Disease Indication
8.4. Analysis by Sensitivity Range
8.5. Analysis by Specificity Range
8.6. Analysis by Turnaround Time
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Point-of-Care Diagnostics for Infectious Diseases: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Product
9.3.4. Analysis by Target Disease Indication
9.3.5. Analysis by Year and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Regional Analysis
9.3.8. Intercontinental and Intracontinental Agreements
10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Scoring Criteria and Key Assumptions
10.4. Potential Strategic Acquisition Targets in North America
10.5. Potential Strategic Acquisition Targets in Europe
10.6. Potential Strategic Acquisition Targets in Asia-Pacific
10.7. Potential Strategic Acquisition Targets in Latin America
10.8. Potential Strategic Acquisition Targets in Middle East, North Africa, and Rest of the World
10.9. Concluding Remarks
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020-2025
11.4. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Target Disease Indication
11.4.1. Point-of-Care Diagnostics Market for COVID-19, 2020-2025
11.4.2. Point-of-Care Diagnostics Market for Chikungunya, 2020-2025
11.4.3. Point-of-Care Diagnostics Market for Dengue, 2020-2025
11.4.4. Point-of-Care Diagnostics Market for Ebola, 2020-2025
11.4.5. Point-of-Care Diagnostics Market for Hepatitis, 2020-2025
11.4.6. Point-of-Care Diagnostics Market for HIV/AIDS, 2020-2025
11.4.7. Point-of-Care Diagnostics Market for Influenza, 2020-2025
11.4.8. Point-of-Care Diagnostics Market for Malaria, 2020-2025
11.4.9. Point-of-Care Diagnostics Market for Pneumonia, 2020-2025
11.4.10. Point-of-Care Diagnostics Market for Tuberculosis, 2020-2025
11.4.11. Point-of-Care Diagnostics Market for Zika, 2020-2025
11.5. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Type of Technology
11.5.1. Point-of-Care Diagnostics for Infectious Diseases Market for Lateral Flow Assay, 2020-2025
11.5.2. Point-of-Care Diagnostics for Infectious Diseases Market for Molecular Diagnostics, 2020-2025
11.5.3. Point-of-Care Diagnostics for Infectious Diseases Market for Fluorescence Immunoassay, 2020-2025
11.5.4. Point-of-Care Diagnostics for Infectious Diseases Market for Solid Phase Assay, 2020-2025
11.5.5. Point-of-Care Diagnostics for Infectious Diseases Market for Other Technologies, 2020-2025
11.6. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Geography
11.6.1. Point-of-Care Diagnostics for Infectious Diseases Market in the US, 2020-2025
11.6.2. Point-of-Care Diagnostics for Infectious Diseases Market in Canada, 2020-2025
11.6.3. Point-of-Care Diagnostics for Infectious Diseases Market in the UK, 2020-2025
11.6.4. Point-of-Care Diagnostics for Infectious Diseases Market in Germany, 2020-2025
11.6.5. Point-of-Care Diagnostics for Infectious Diseases Market in Spain, 2020-2025
11.6.6. Point-of-Care Diagnostics for Infectious Diseases Market in France, 2020-2025
11.6.7. Point-of-Care Diagnostics for Infectious Diseases Market in Italy, 2020-2025
11.6.8. Point-of-Care Diagnostics for Infectious Diseases Market in China, 2020-2025
11.6.9. Point-of-Care Diagnostics for Infectious Diseases Market in India, 2020-2025
11.6.10. Point-of-Care Diagnostics for Infectious Diseases Market in Japan, 2020-2025
11.6.11. Point-of-Care Diagnostics for Infectious Diseases Market in Australia, 2020-2025
11.6.12. Point-of-Care Diagnostics for Infectious Diseases Market in Brazil, 2020-2025
11.6.13. Point-of-Care Diagnostics for Infectious Diseases Market in Argentina, 2020-2025
11.6.14. Point-of-Care Diagnostics for Infectious Diseases Market in Saudi Arabia, 2020-2025
11.6.15. Point-of-Care Diagnostics for Infectious Diseases Market in UAE, 2020-2025
11.6.16. Point-of-Care Diagnostics for Infectious Diseases Market in Egypt, 2020-2025
11.6.17. Point-of-Care Diagnostics for Infectious Diseases Market in South Africa, 2020-2025
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Proactive Diagnostics
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Reuven Duer, Founder and Chief Executive Officer
12.3. UrSure
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Giffin Daughtridge, Chief Executive Officer
12.4. Accurex Biomedical
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Abhinav Thakur, Managing Director
12.5. Hemex Health
12.5.1. Company Snapshot
12.5.2. Interview Transcript: Gerrit Van Roekel, Director of Business Development
12.6. Credo Diagnostics Biomedical
12.6.1. Company Snapshot
12.6.2. Interview Transcript: Sofiane Bennacer, Business Development Manager
13. CONCLUDING REMARKS
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 The ASSURED Criteria for an Ideal Point-of-Care Diagnostics
Figure 3.2 Technologies Used in Point-of-Care Diagnostics for Infectious Diseases
Figure 4.1 Point-of-Care Diagnostics for COVID-19: Distribution by Status of Development
Figure 4.2 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Product
Figure 4.3 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Technology
Figure 4.4 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Sample
Figure 4.5 Point-of-Care Diagnostics for COVID-19: Distribution by Sensitivity Range
Figure 4.6 Point-of-Care Diagnostics for COVID-19: Distribution by Specificity Range
Figure 4.7 Point-of-Care Diagnostics for COVID-19: Distribution by Turnaround Time
Figure 4.8 Point-of-Care Diagnostics for COVID-19: Distribution of Developers by Year of Establishment
Figure 4.9 Point-of-Care Diagnostics for COVID-19: Distribution of Developers by Company Size and Geographical Location
Figure 4.10 Leading Players: Distribution by Number of Products
Figure 4.11 World Map Representation: Distribution by Regional Activity
Figure 5.1 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Status of Development
Figure 5.2 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Product
Figure 5.3 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Technology
Figure 5.4 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Target Disease Indication
Figure 5.5 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Sample
Figure 5.6 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Sensitivity Range
Figure 5.7 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Specificity Range
Figure 5.8 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Turnaround Time
Figure 5.9 Point-of-Care Diagnostics for Tropical Diseases: Distribution of Developers by Year of Establishment
Figure 5.10 Point-of-Care Diagnostics for Tropical Diseases: Distribution of Developers by Company Size and Geographical Location
Figure 5.11 Leading Players: Distribution by Number of Products
Figure 5.12 World Map Representation: Distribution by Regional Activity
Figure 6.1 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Status of Development
Figure 6.2 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Product
Figure 6.3 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Technology
Figure 6.4 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Target Disease Indication
Figure 6.5 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Sample
Figure 6.6 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Sensitivity Range
Figure 6.7 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Specificity Range
Figure 6.8 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Turnaround Time
Figure 6.9 Point-of-Care Diagnostics for Respiratory Infections: Distribution of Developers by Year of Establishment
Figure 6.10 Point-of-Care Diagnostics for Respiratory Infections: Distribution of Developers by Company Size and Geographical Location
Figure 6.11 Leading Players: Distribution by Number of Products
Figure 6.12 World Map Representation: Distribution by Regional Activity
Figure 7.1 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Status of Development
Figure 7.2 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Product
Figure 7.3 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Technology
Figure 7.4 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Target Disease Indication
Figure 7.5 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Sample
Figure 7.6 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Sensitivity Range
Figure 7.7 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Specificity Range
Figure 7.8 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Turnaround Time
Figure 7.9 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution of Developers by Year of Establishment
Figure 7.10 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution of Developers by Company Size and Geographical Location
Figure 7.11 Leading Players: Distribution by Number of Products
Figure 7.12 World Map Representation: Distribution by Regional Activity
Figure 8.1 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Type of Technology
Figure 8.2 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Target Disease Indication
Figure 8.3 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Sensitivity Range
Figure 8.4 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Specificity Range
Figure 8.5 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Turnaround Time
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2020 (till July)
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 9.6 Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 9.7 Partnerships and Collaborations: Distribution by Year and Type of Partner
Figure 9.8 Most Active Players: Distribution by Number of Partnerships
Figure 9.9 Partnerships and Collaborations: Regional Distribution
Figure 9.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Likely Acquisition Targets: Geographical Distribution
Figure 11.1 Global Point-of-Care for Infectious Diseases Market, 2020-2025 (USD Million)
Figure 11.2 Global Point-of-Care for Infectious Diseases Market, 2020 and 2025: Distribution by Target Disease Indication (USD Million)
Figure 11.3 Point-of-Care Diagnostics Market for COVID-19, 2020-2025 (USD Million)
Figure 11.4 Point-of-Care Diagnostics Market for Chikungunya, 2020-2025 (USD Million)
Figure 11.5 Point-of-Care Diagnostics Market for Dengue, 2020-2025 (USD Million)
Figure 11.6 Point-of-Care Diagnostics Market for Ebola, 2020-2025 (USD Million)
Figure 11.7 Point-of-Care Diagnostics Market for Hepatitis, 2020-2025 (USD Million)
Figure 11.8 Point-of-Care Diagnostics Market for HIV/AIDS, 2020-2025 (USD Million)
Figure 11.9 Point-of-Care Diagnostics Market for Influenza, 2020-2025 (USD Million)
Figure 11.10 Point-of-Care Diagnostics Market for Malaria, 2020-2025 (USD Million)
Figure 11.11 Point-of-Care Diagnostics Market for Pneumonia, 2020-2025 (USD Million)
Figure 11.12 Point-of-Care Diagnostics Market for Tuberculosis, 2020-2025 (USD Million)
Figure 11.13 Point-of-Care Diagnostics Market for Zika, 2020-2025 (USD Million)
Figure 11.14 Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Type of Technology (USD Million)
Figure 11.15 Point-of-Care Diagnostics for Infectious Diseases Market for Lateral Flow Assay, 2020-2025 (USD Million)
Figure 11.16 Point-of-Care Diagnostics for Infectious Diseases Market for Molecular Diagnostics, 2020-2025 (USD Million)
Figure 11.17 Point-of-Care Diagnostics for Infectious Diseases Market for Fluorescence Immunoassay, 2020-2025 (USD Million)
Figure 11.18 Point-of-Care Diagnostics for Infectious Diseases Market for Solid Phase Assay, 2020-2025 (USD Million)
Figure 11.19 Point-of-Care Diagnostics for Infectious Diseases Market for Other Technologies, 2020-2025 (USD Million)
Figure 11.20 Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Geography (USD Million)
Figure 11.21 Point-of-Care Diagnostics for Infectious Diseases Market in the US, 2020-2025 (USD Million)
Figure 11.22 Point-of-Care Diagnostics for Infectious Diseases Market in Canada, 2020-2025 (USD Million)
Figure 11.23 Point-of-Care Diagnostics for Infectious Diseases Market in the UK, 2020-2025 (USD Million)
Figure 11.24 Point-of-Care Diagnostics for Infectious Diseases Market in Germany, 2020-2025 (USD Million)
Figure 11.25 Point-of-Care Diagnostics for Infectious Diseases Market in Spain, 2020-2025 (USD Million)
Figure 11.26 Point-of-Care Diagnostics for Infectious Diseases Market in France, 2020-2025 (USD Million)
Figure 11.27 Point-of-Care Diagnostics for Infectious Diseases Market in Italy, 2020-2025 (USD Million)
Figure 11.28 Point-of-Care Diagnostics for Infectious Diseases Market in China, 2020-2025 (USD Million)
Figure 11.29 Point-of-Care Diagnostics for Infectious Diseases Market in India, 2020-2025 (USD Million)
Figure 11.30 Point-of-Care Diagnostics for Infectious Diseases Market in Japan, 2020-2025 (USD Million)
Figure 11.31 Point-of-Care Diagnostics for Infectious Diseases Market in Australia, 2020-2025 (USD Million)
Figure 11.32 Point-of-Care Diagnostics for Infectious Diseases Market in Brazil, 2020-2025 (USD Million)
Figure 11.33 Point-of-Care Diagnostics for Infectious Diseases Market in Argentina, 2020-2025 (USD Million)
Figure 11.34 Point-of-Care Diagnostics for Infectious Diseases in Saudi Arabia, 2020-2025 (USD Million)
Figure 11.35 Point-of-Care Diagnostics for Infectious Diseases Market in UAE, 2020-2025 (USD Million)
Figure 11.36 Point-of-Care Diagnostics for Infectious Diseases Market in Egypt, 2020-2025 (USD Million)
Figure 11.37 Point-of-Care Diagnostics for Infectious Diseases Market in South Africa, 2020-2025 (USD Million)
Table 4.1 Point-of-Care Diagnostics for COVID-19: List of Products
Table 4.2 Point-of-Care Diagnostics for COVID-19: List of Developers
Table 5.1 Point-of-Care Diagnostics for Tropical Diseases: List of Products
Table 5.2 Point-of-Care Diagnostics for Tropical Diseases: List of Developers
Table 6.1 Point-of-Care Diagnostics for Respiratory Infections: List of Products
Table 6.2 Point-of-Care Diagnostics for Respiratory Infections: List of Developers
Table 7.1 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Products
Table 7.2 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Developers
Table 9.1 Point-of-Care Diagnostics for Infectious Diseases: List of Partnerships and Collaborations
Table 10.1 North America: Likely Targets for Acquisition
Table 10.2 Europe: Likely Targets for Acquisition
Table 10.3 Asia-Pacific: Likely Targets for Acquisition
Table 10.4 Latin America: Likely Targets for Acquisition
Table 10.5 Middle East, North Africa, and Rest of the World: Likely Targets for Acquisition
Table 12.1 Proactive Diagnostics: Company Snapshot
Table 12.2 UrSure: Company Snapshot
Table 12.3 Accurex Biomedical: Company Snapshot
Table 12.4 Hemex Health: Company Snapshot
Table 12.5 Credo Diagnostics Biomedical: Company Snapshot
Table 14.1 Point-of-Care Diagnostics for COVID-19: Distribution by Status of Development
Table 14.2 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Product
Table 14.3 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Technology
Table 14.4 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Sample
Table 14.5 Point-of-Care Diagnostics for COVID-19: Distribution by Sensitivity Range
Table 14.6 Point-of-Care Diagnostics for COVID-19: Distribution by Specificity Range
Table 14.7 Point-of-Care Diagnostics for COVID-19: Distribution by Turnaround Time
Table 14.8 Point-of-Care Diagnostics for COVID-19: Distribution of Developers by Year of Establishment
Table 14.9 Point-of-Care Diagnostics for COVID-19: Distribution of Developers by Company Size and Geographical Location
Table 14.10 Leading Players: Distribution by Number of Products
Table 14.11 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Status of Development
Table 14.12 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Product
Table 14.13 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Technology
Table 14.14 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Target Disease Indication
Table 14.15 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Sample
Table 14.16 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Sensitivity Range
Table 14.17 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Specificity Range
Table 14.18 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Turnaround Time
Table 14.19 Point-of-Care Diagnostics for Tropical Diseases: Distribution of Developers by Year of Establishment
Table 14.20 Point-of-Care Diagnostics for Tropical Diseases: Distribution of Developers by Company Size and Geographical Location
Table 14.21 Leading Players: Distribution by Number of Products
Table 14.22 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Status of Development
Table 14.23 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Product
Table 14.24 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Technology
Table 14.25 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Target Disease Indication
Table 14.26 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Sample
Table 14.27 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Sensitivity Range
Table 14.28 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Specificity Range
Table 14.29 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Turnaround Time
Table 14.30 Point-of-Care Diagnostics for Respiratory Infections: Distribution of Developers by Year of Establishment
Table 14.31 Point-of-Care Diagnostics for Respiratory Infections: Distribution of Developers by Company Size and Geographical Location
Table 14.32 Leading Players: Distribution by Number of Products
Table 14.33 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Status of Development
Table 14.34 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Product
Table 14.35 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Technology
Table 14.36 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Target Disease Indication
Table 14.37 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Sample
Table 14.38 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Sensitivity Range
Table 14.39 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Specificity Range
Table 14.40 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Turnaround Time
Table 14.41 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution of Developers by Year of Establishment
Table 14.42 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution of Developers by Company Size and Geographical Location
Table 14.43 Leading Players: Distribution by Number of Products
Table 14.44 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Type of Technology
Table 14.45 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Target Disease Indication
Table 14.46 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Sensitivity Range
Table 14.47 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Specificity Range
Table 14.48 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Turnaround Time
Table 14.49 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2020 (till July)
Table 14.50 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.51 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.52 Partnerships and Collaborations: Distribution by Type of Product
Table 14.53 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 14.54 Partnerships and Collaborations: Distribution by Target Disease Indication
Table 14.55 Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 15.56 Most Active Players: Distribution by Number of Partnerships
Table 14.57 Partnerships and Collaborations: Regional Distribution
Table 14.58 Likely Acquisition Targets: Geographical Distribution
Table 14.59 Global Point-of-Care for Infectious Diseases Market, 2020-2025 (USD Million)
Table 14.60 Global Point-of-Care for Infectious Diseases Market, 2020 and 2025: Distribution by Target Disease Indication (USD Million)
Table 14.61 Point-of-Care Diagnostics Market for COVID-19, 2020-2025 (USD Million)
Table 14.62 Point-of-Care Diagnostics Market for Chikungunya, 2020-2025 (USD Million)
Table 14.63 Point-of-Care Diagnostics Market for Dengue, 2020-2025 (USD Million)
Table 14.64 Point-of-Care Diagnostics Market for Ebola, 2020-2025 (USD Million)
Table 14.65 Point-of-Care Diagnostics Market for Hepatitis, 2020-2025 (USD Million)
Table 14.66 Point-of-Care Diagnostics Market for HIV/AIDS, 2020-2025 (USD Million)
Table 14.67 Point-of-Care Diagnostics Market for Influenza, 2020-2025 (USD Million)
Table 14.68 Point-of-Care Diagnostics Market for Malaria, 2020-2025 (USD Million)
Table 14.69 Point-of-Care Diagnostics Market for Pneumonia, 2020-2025 (USD Million)
Table 14.70 Point-of-Care Diagnostics Market for Tuberculosis, 2020-2025 (USD Million)
Table 14.71 Point-of-Care Diagnostics Market for Zika, 2020-2025 (USD Million)
Table 14.72 Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Type of Technology (USD Million)
Table 14.73 Point-of-Care Diagnostics for Infectious Diseases Market for Lateral Flow Assay, 2020-2025 (USD Million)
Table 14.74 Point-of-Care Diagnostics for Infectious Diseases Market for Molecular Diagnostics, 2020-2025 (USD Million)
Table 14.75 Point-of-Care Diagnostics for Infectious Diseases Market for Fluorescence Immunoassay, 2020-2025 (USD Million)
Table 14.76 Point-of-Care Diagnostics for Infectious Diseases Market for Solid Phase Assay, 2020-2025 (USD Million)
Table 14.77 Point-of-Care Diagnostics for Infectious Diseases Market for Other Technologies, 2020-2025 (USD Million)
Table 14.78 Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Geography (USD Million)
Table 14.79 Point-of-Care Diagnostics for Infectious Diseases Market in the US, 2020-2025 (USD Million)
Table 14.80 Point-of-Care Diagnostics for Infectious Diseases Market in Canada, 2020-2025 (USD Million)
Table 14.81 Point-of-Care Diagnostics for Infectious Diseases in the UK, 2020-2025 (USD Million)
Table 14.82 Point-of-Care Diagnostics for Infectious Diseases Market in Germany, 2020-2025 (USD Million)
Table 14.83 Point-of-Care Diagnostics for Infectious Diseases Market in Spain, 2020-2025 (USD Million)
Table 14.84 Point-of-Care Diagnostics for Infectious Diseases Market in France, 2020-2025 (USD Million)
Table 14.85 Point-of-Care Diagnostics for Infectious Diseases Market in Italy, 2020-2025 (USD Million)
Table 14.86 Point-of-Care Diagnostics for Infectious Diseases Market in China, 2020-2025 (USD Million)
Table 14.87 Point-of-Care Diagnostics for Infectious Diseases Market in India, 2020-2025 (USD Million)
Table 14.88 Point-of-Care Diagnostics for Infectious Diseases Market in Japan, 2020-2025 (USD Million)
Table 14.89 Point-of-Care Diagnostics for Infectious Diseases Market in Australia, 2020-2025 (USD Million)
Table 14.90 Point-of-Care Diagnostics for Infectious Diseases Market in Brazil, 2020-2025 (USD Million)
Table 14.91 Point-of-Care Diagnostics for Infectious Diseases Market in Argentina, 2020-2025 (USD Million)
Table 14.92 Point-of-Care Diagnostics for Infectious Diseases Market in Saudi Arabia, 2020-2025 (USD Million)
Table 14.93 Point-of-Care Diagnostics for Infectious Diseases Market in UAE, 2020-2025 (USD Million)
Table 14.94 Point-of-Care Diagnostics for Infectious Diseases Market in Egypt, 2020-2025 (USD Million)
Table 14.95 Point-of-Care Diagnostics for Infectious Diseases Market in South Africa, 2020-2025 (USD Million)
Please reach out to our team for more details.
Source 1: www.who.int/bulletin/volumes/83/3/interview0305/en/
Source 2: www.ncbi.nlm.nih.gov/pmc/articles/PMC3722505/